Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur

Playlist - Dr. Alison Conlin & Dr. Heather McArthur

Beyond KATHERINE: The DB-05 Shift in High-Risk HER2+ Disease

1 min read

Does Higher pCR Come at a Cost? Weighing Efficacy vs Toxicity in DB-11

1 min read

“Best Drug on Earth” Isn’t Enough If Patients Can’t Tolerate It

1 min read

Is pCR Enough? Why Regulators Still Want EFS Data

1 min read

Eliminating the Surprise: Mapping the Path for Adjuvant Therapy After Surgery

1 min read

HER2+ Breast Cancer: The Most Transformed Disease in Oncology?

1 min read